IDEMIA
10.12.2020 17:47:11 CET | Business Wire | Press release
IDEMIA, the global leader in Augmented Identity, and Kudelski IoT, a division of the Kudelski Group (SIX: KUD.S), the world leader in digital security and IoT solutions, today announced a joint solution for mobile network operators (MNOs), mobile virtual network operators (MVNOs), original equipment manufacturers (OEMs) and service providers to enable efficient IoT device provisioning at scale, without compromising on connectivity or data security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005726/en/
With the growth of IoT deployments globally, the security of devices and client data stored or collected within the device has become one of the biggest concerns across the ecosystem and its users. IDEMIA, member of the Trusted Connectivity Alliance (TCA1 ), and Kudelski IoT are taking on the challenge of data privacy and device protection with a simplified, end-to-end security solution for IoT deployments designed to securely connect devices to the cloud. This solution is particularly relevant since OEMs and service providers are looking for solutions using embedded Secure Elements to protect content.
IDEMIA’s IoT SAFE solution provides the added benefit of remote management and provisioning of over-the-air (OTA) security certificates and application updates directly to the highly secure SIM environment. This also provides the ability to keep the solution up-to-date with evolving security standards.
By seamlessly integrating the Kudelski IoT Root of Trust applet and keySTREAM system within IDEMIA’s secure elements and OTA platform, OEMs, MNOs and service providers now have a solution to leverage for their own security services for their customers and end users.
The combination of IDEMIA and Kudelski’s leading positions within their respective areas of excellence ensures a simplified approach to enabling security for IoT devices and platforms, allowing plug & play installation for connected security use cases.
“The industry has been expecting standards to be defined for IoT Security. Together with GSMA and the TCA, those standards and guidelines are now in place with IoT SAFE. Thanks to our partnership with Kudelski, IDEMIA is proud to bring this technology breakthrough solution to the market. The market can now benefit from an independent technology with the added benefit of ensuring end-to-end device and data security for IoT,” said Fabien Jautard Executive Vice-President for Mobile Operators activities at IDEMIA.
“By combining IDEMIA’s Mobile Network SIMs and OTA platform with Kudelski IoT keySTREAM into a solution specifically tailored for cellular machine-to-machine communications, we bring to the market the first truly standard and dedicated end-to-end IoT security solution for mobile networks,” said Hardy Schmidbauer, SVP, Kudelski IoT.
1 TCA is a global, non-profit industry association which is working to enable a secure connected future. Its members are participants within the SIM ecosystem, which is the most widely distributed, secure application delivery platform in the world.
About IDEMIA’s Mobile Operators Business unit
IDEMIA serves clients in 180 countries and is trusted by over 500 mobile operators globally. With over 850 million SIM cards, 100 + eSIM platform references and over 2.2 eSIM consumer transactions in 2019, IDEMIA is leading the way in eSIM and remote subscription management for consumer and M2M spaces and end-to-end biometric solutions. Making MNOs the next identity providers. IDEMIA benefits from its global manufacturing footprint (Brazil, France, India and China) and cutting-edge security data centers in Europe and the United States. Our solutions are trusted by the largest Groups worldwide. Our Continuous innovation is fueled by strong R&D investments and close partnerships in IoT/M2M - Connectivity - Biometrics – Security – Encryption – QoS/QoE – Advanced SIM & services areas.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
About Kudelski IOT
Kudelski IoT is the Internet of Things division of The Kudelski Group and provides end-to-end IoT solutions, IoT product design, and full-lifecycle services to IoT device manufacturers, ecosystem creators and end-user companies. These solutions and services leverage the group’s 30+ years of innovation in digital business model creation; hardware, software and ecosystem design and testing; state-of-the-art security lifecycle management technologies and services and managed operation of complex systems. For more information about Kudelski IOT, please visit www.kudelski-iot.com .
About Kudelski Group
The Kudelski Group (SIX: KUD.S) is a world leader in digital security and a provider of end-to-end convergent media solutions to the digital entertainment industry, including services and applications requiring access control and rights management to secure the revenue in digital television, internet, mobile and interactive applications. The Group also offers cybersecurity solutions and services focused on helping companies assess risks and vulnerabilities and protect their data and systems. It also supplies integrated solutions to manage access control of people and vehicles to sites and events. The Kudelski Group is headquartered in Cheseaux-sur-Lausanne, Switzerland and Phoenix (AZ), USA. For more information, please visit www.nagra.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005726/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
